Avalo Therapeutics heads into the back half of June with a striking split: short sellers hold a third of the float while every analyst covering the stock rates it a Buy.
The short positioning is the most immediate tension. At 35.5% of the free float, short interest has climbed 28% over the past month — the bulk of that build appears concentrated in the second half of May, when shares short jumped from roughly 4.8 million to over 6.3 million in the week ending June 8. That's a meaningful structural shift, not a rounding error. The ORTEX short score has responded accordingly, rising to 67.9 — its highest reading in the ten-day window visible here and up from 61.3 less than two weeks ago. The borrow market, however, tells a more relaxed story: cost to borrow is only 0.76%, down sharply from the 1.78% seen in early May, and availability runs at 156% — meaning lenders currently have roughly 1.5 shares available for every share already borrowed. That is a normal-to-tight lending environment, not a squeeze-risk setup. The factor scores corroborate: days-to-cover ranks in only the 39th percentile, and the short score rank itself sits at the 19th percentile of the broader universe, suggesting the absolute level of short interest is elevated but not unusual enough to alarm the wider market's ranking algorithms.
Options traders are leaning the other way. The put/call ratio is running below its recent average — 0.55 versus the 20-day mean of 0.60 — and the z-score of -1.5 places it modestly into call-heavy territory. That is not an aggressive bull signal, but it does contrast clearly with the short-side conviction: options positioning looks more sanguine than short interest would imply. The 52-week range for the PCR runs from 0.13 to 5.42, which underscores just how wide the sentiment swings have been on this name historically; the current reading is calm by comparison.
The Street is uniformly constructive, though target prices vary considerably. Bank of America initiated coverage this week with a Buy and a $35 target. BTIG reiterated its Buy and a $58 target on the same day. The range — $34 at Wedbush to $60 at Piper Sandler — reflects genuine disagreement about the pace and scope of abdakibart's potential, rather than directional doubt. The consensus mean target of $45.25 implies more than 200% upside to Monday's close of $14.33, though that gap largely reflects the stock's retreat from late-May highs above $24 rather than any fundamental revision. The bull case centres on the Phase 2 LOTUS trial data for abdakibart and a pipeline that includes quisovalimab and AVTX-008. The bear case is harder to dismiss entirely: the prior lead candidate AVTX-009 stumbled, cash burn continues, and the company has no revenue. Analyst recommendation differentiation ranks at the 92nd percentile — the broadest bullish spread in the universe by that measure — which paradoxically signals that the consensus is so one-sided it may already be priced in.
Institutional ownership adds a layer of interest. Deep Track Capital and TCG Crossover Management each entered the register with full new positions (their reported changes equal their entire holdings), joining Point72, which added nearly 1.8 million shares, and T. Rowe Price, which built essentially a new position of over 2.1 million shares. Several of these moves are reported through May, so they reflect buying into the Phase 2 catalyst window. On the insider side, the 90-day net figure shows roughly 295,000 shares and ~$5.9 million in net value — but the recent trade log is exclusively sells, with the CMO, CFO, CLO, and Chief Strategy Officer all selling small lots on June 10. The values are trivial ($1,800 to $14,200), and significance scores rank at 1, suggesting routine plan-driven disposals rather than a directional signal.
Earnings reaction history warrants attention with the next print due August 7. The three most recent events each produced negative one-day moves: -12.8%, -4.7%, and -11.5%, with five-day drifts of -18%, -18%, and -22% respectively. The prior event, in March 2026, was the outlier — a -0.4% first-day move followed by a +27% five-day run. That asymmetry is worth keeping in mind: when the catalyst is clinical rather than financial, the stock's pattern has been to sell the announcement and then either extend losses or recover sharply depending on the read-through, making the August event binary in character rather than a simple beat-or-miss dynamic.
The August 7 report will be less about quarterly financials and more about any update on the registrational trial timeline for abdakibart — and whether the institutional buyers who stepped in during May are willing to hold through what has historically been a volatile post-announcement window.
See the live data behind this article on ORTEX.
Open AVTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
